BEGIN:VCALENDAR
PRODID:-//AddEvent Inc//AddEvent.com v1.7//EN
VERSION:2.0
BEGIN:VTIMEZONE
TZID:America/Phoenix
BEGIN:STANDARD
DTSTART:19691231T170000
TZOFFSETFROM:-0700
TZOFFSETTO:-0700
TZNAME:MST
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Join National Jewish Health in person or via livestream for this CME symposium at CHEST 2026. Register at NJHealth.org/SevereAsthma  http://NJHealth.org/SevereAsthma\n\nSevere asthma is associated with substantial morbidity\, frequent exacerbations\, and a high treatment burden despite available therapies. A significant proportion of patients exhibit Type 2 inflammation\, including eosinophilic phenotypes\, for which targeted biologic therapies have meaningfully improved disease control and reduced exacerbations. Recent therapeutic advances represent an important evolution in severe asthma management by introducing extended dosing intervals that have the potential to reduce treatment burden\, support long-term adherence\, and enhance sustained disease control in appropriately selected patients.\n \nIn this CME symposium\, an expert panel of pulmonologists and allergists will discuss barriers to care\, multidisciplinary collaboration\, and the evolving treatment landscape in severe asthma. Throughout this case-based discussion\, panelists will explore common challenges in severe asthma treatment\, such as treatment escalation\, shared decision-making\, long-term disease control\, and the impact of comorbidities and access barriers on outcomes.\n\n1.0 CME/MOC\n\nFaculty:\nFlavia Cecilia Lega Hoyte\, MD\nNational Jewish Health\n\nEileen Wang\, MD\, MPH\nNational Jewish Health\n\nMichael E. Wechser\, MD\, MMSc\nNational Jewish Health
X-ALT-DESC;FMTTYPE=text/html:<strong>Join National Jewish Health in person or via livestream for this CME symposium at CHEST 2026. Register at </strong><a href="http://NJHealth.org/SevereAsthma" target="_blank" rel="noopener noreferrer"><strong>NJHealth.org/SevereAsthma </strong></a><br><br>Severe asthma is associated with substantial morbidity, frequent exacerbations, and a high treatment burden despite available therapies. A significant proportion of patients exhibit Type 2 inflammation, including eosinophilic phenotypes, for which targeted biologic therapies have meaningfully improved disease control and reduced exacerbations. Recent therapeutic advances represent an important evolution in severe asthma management by introducing extended dosing intervals that have the potential to reduce treatment burden, support long-term adherence, and enhance sustained disease control in appropriately selected patients.<br /> <br />In this CME symposium, an expert panel of pulmonologists and allergists will discuss barriers to care, multidisciplinary collaboration, and the evolving treatment landscape in severe asthma. Throughout this case-based discussion, panelists will explore common challenges in severe asthma treatment, such as treatment escalation, shared decision-making, long-term disease control, and the impact of comorbidities and access barriers on outcomes.<br><br>1.0 CME/MOC<br><br>Faculty:<br />Flavia Cecilia Lega Hoyte, MD<br />National Jewish Health<br><br>Eileen Wang, MD, MPH<br />National Jewish Health<br><br>Michael E. Wechser, MD, MMSc<br />National Jewish Health
UID:48d52f245e6543d9881fd6f59e54248caddeventcom
SUMMARY:Rethinking Treatment Frequency in Severe Asthma: A Case-Based Discussion of Emerging Evidence and Clinical Implications
DTSTART;TZID=America/Phoenix:20261018T121500
DTEND;TZID=America/Phoenix:20261018T131500
DTSTAMP:20260625T031608Z
TRANSP:OPAQUE
STATUS:CONFIRMED
SEQUENCE:0
LOCATION:Phoenix Convention Center\nNorth Building Room #132\n100 N 3rd St\, Phoenix\, 85004\, AZ\, USA
X-MICROSOFT-CDO-BUSYSTATUS:BUSY
BEGIN:VALARM
TRIGGER:-PT60M
ACTION:DISPLAY
DESCRIPTION:Reminder
END:VALARM
END:VEVENT
END:VCALENDAR